Two patients with HAE type I additionally received a LTP with pd-C1-INH-concentrate IV once a week (P4) or twice a week (P9), while the 2 patients with HAE-nC1-INH (P11 and P12) had received LTP with Lanadelumab 300mg SC with loss of efficacy. This evidence concerns the gene COL18A1 and hereditary angioedema.